The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://umarnhbj221536.corpfinwiki.com/9471449/retatrutide_vs_tirzepatide_a_comparative_analysis